Eph-B2/Ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 91-104

  Azab, Feda ^a   Azab, Abdel Kareem ^a   Maiso, Patricia ^a   Calimeri, Teresa ^a   Flores, Ludmila ^a   Liu, Yang ^a   Quang, Phong ^a   Roccaro, Aldo M ^a   Sacco, Antonio ^a   Ngo, Hai T ^a   Zhang, Yong ^a   Morgan, Brittany L ^a   Carrasco, Ruben D ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; COFILIN; EPHRIN B2; EPHRIN RECEPTOR B2; FOCAL ADHESION KINASE; PAXILLIN; PROTEIN P130; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL CYCLE; CELL ISOLATION; CELL PROLIFERATION; CHEMOTAXIS; COCULTURE; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; CASE-CONTROL STUDIES; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; EPHRIN-B2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MICE; MICE, SCID; NEOVASCULARIZATION, PHYSIOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, EPH FAMILY; RNA, MESSENGER; RNA, SMALL INTERFERING; STROMAL CELLS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84855417609     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0111     Document Type: Article

References (33)

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.
2. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87. (Pubitemid 41058349)
3. Gale NW, Holland SJ, Valenzuela DM, Flenniken A, Pan L, Ryan TE, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996;17:9-19. (Pubitemid 26251587)
4. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005;6:462-75. (Pubitemid 40780558)
5. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008;133:38-52. (Pubitemid 351442996)
6. Durbin L, Brennan C, Shiomi K, Cooke J, Barrios A, Shanmugalingam S, et al. Eph signaling is required for segmentation and differentiation of the somites. Genes Dev 1998;12:3096-109. (Pubitemid 28469310)
7. Pasquale EB, Deerinck TJ, Singer SJ, Ellisman MH. Cek5, a membrane receptor-type tyrosine kinase, is in neurons of the embryonic and postnatal avian brain. J Neurosci 1992;12:3956-67.
8. Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 2007;17:230-8. (Pubitemid 46679245)
9. Gerlai R. Eph receptors and neural plasticity. Nat Rev Neurosci 2001;2:205-9. (Pubitemid 33673373)
10. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005;5:149-57. (Pubitemid 40694857)
11. Rosenberg IM, Goke M, Kanai M, Reinecker HC, Podolsky DK. Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 1997;273:G824-32.
12. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-5.
13. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007;109:5096-103.
14. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008;112:150-8.
15. Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, et al. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res 2009;15:6035-41.
16. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009;114:619-29.
17. Ria R, Vacca A, Russo F, Cirulli T, Massaia M, Tosi P, et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004;92:1438-45. (Pubitemid 39642557)
18. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003;88:176-85. (Pubitemid 37101495)
19. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62. (Pubitemid 43726814)
20. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-80.
21. Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, et al. FGFR3 is overexpressed Waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res 2011;17:4389-99.
22. Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res 2011;17:1753-64.
23. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010;465:487-91.
24. Terpos E, Tasidou A, Kastritis E, Eleftherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, et al. Angiogenesis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:46-9.
25. Bourgin C, Murai KK, Richter M, Pasquale EB. The EphA4 receptor regulates dendritic spine remodeling by affecting beta1-integrin signaling pathways. J Cell Biol 2007;178:1295-307. (Pubitemid 47480233)
26. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002;3:475-86. (Pubitemid 34733429)
27. Poliakov A, Cotrina M, Wilkinson DG. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 2004;7:465-80. (Pubitemid 39341833)
28. Vindis C, Teli T, Cerretti DP, Turner CE, Huynh-Do U. EphB1-mediated cell migration requires the phosphorylation of paxillin at Tyr-31/Tyr-118. J Biol Chem 2004;279:27965-70. (Pubitemid 38900065)
29. Carter N, Nakamoto T, Hirai H, Hunter T. EphrinA1-induced cytoskeletal re-organization requires FAK and p 130(cas). Nat Cell Biol 2002;4:565-73.
30. Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 2004;64:781-8. (Pubitemid 38176871)
31. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010;465:483-6.
32. Salvucci O, de la Luz Sierra M, Martina JA, McCormick PJ, Tosato G. EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood 2006;108:2914-22.
33. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD Jr, Barlogie B, et al. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 2009;114:1803-12.